Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Tourist trade in Greece and Cyprus suffering from Iran war effects - 2NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- 3Beating Wellbeing Difficulties: Individual Victories in Health
- 4Purdue Pharma's deal means money for some victims, end of Purdue company name. Here's what to know
- 5Simple Consideration Plants for Home and Office: An Aide
- Africa's energy giants eye long-term gains on Iran war disruption
- How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- Remain Fit: Powerful Wellness and Work-out Schedules for a Better You
- New COVID-19 variant 'Cicada' is spreading. What to know about BA.3.2.
- Venice’s newest marvel is a wild, acrobatic dolphin. His refusal to leave puts him in danger
- The many ways that baking is winter therapy. With a delicious ending
- Protest inspired by 'Gen Z' movement draws few young people in Mexico and many government critics
- Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- Artemis II crew take new photo of far side of the moon
